Feature | Published:

Nature Biotechnology's academic spinouts of 2017

Nature Biotechnology volume 36, pages 297306 (2018) | Download Citation

Subjects

This article has been updated

Our annual survey highlights how immune-oncology and screens based on the application of cutting-edge omics technologies are providing a launchpad for a succession of startups interrogating biology across biomedicine.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 15 May 2018

    In the version of this article initially published, the name and photo of Viviane Tabar, one of BlueRock's founders, was omitted. A misplaced '&' in the author list in the PDF has been corrected, and the abbreviation MSKCC added in the text. The errors have been corrected in the HTML and PDF versions of the article.

References

  1. 1.

    Natural killer cells blaze into immuno-oncology. Nat. Biotechnol. 34, 219–220 (2016).

  2. 2.

    et al. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J. Clin. Invest. 124, 4781–4794 (2014).

  3. 3.

    et al. Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science 348, 136–139 (2015).

  4. 4.

    et al. Endothelial cells express NKG2D ligands and desensitize antitumor NK responses. eLife 6, e30881 (2017).

  5. 5.

    et al. Chemoproteomic profiling and discovery of protein electrophiles in human cells. Nat. Chem. 9, 234–243 (2017).

  6. 6.

    et al. A natural product inhibits the initiation of a-synuclein aggregation and suppresses its toxicity. Proc. Natl. Acad. Sci. USA 114, E1009–E1017 (2017).

  7. 7.

    , , , & Alpha-synuclein disease mutations are structurally defective and locally affect membrane binding. J. Am. Chem. Soc. 139, 4254–4257 (2017).

  8. 8.

    et al. Vagotomy and subsequent risk of Parkinson's disease. Ann. Neurol. 78, 522–529 (2015).

  9. 9.

    et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480, 547–551 (2011).

  10. 10.

    et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510, 273–277 (2014).

  11. 11.

    et al. Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. Nature 538, 388–391 (2016).

  12. 12.

    et al. Rare, high-affinity mouse anti-PD-1 antibodies that function in checkpoint blockade, discovered using microfluidics and molecular genomics. MAbs 9, 1270–1281 (2017).

  13. 13.

    et al. Rare, high-affinity anti-pathogen antibodies from human repertoires, discovered using microfluidics and molecular genomics. MAbs 9, 1282–1296 (2017).

  14. 14.

    Recasting natural product research. Nat. Biotechnol. 30, 385–387 (2012).

  15. 15.

    et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell 163, 1515–1526 (2015).

  16. 16.

    et al. Mammalian polymerase q promotes alternative NHEJ and suppresses recombination. Nature 518, 254–257 (2015).

  17. 17.

    et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).

  18. 18.

    et al. High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature 509, 487–491 (2014).

  19. 19.

    et al. Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library. Nat. Biotechnol. 34, 1279–1286 (2016).

  20. 20.

    , , , & Integrating genetic approaches into the discovery of anticancer drugs. Science 278, 1064–1068 (1997).

  21. 21.

    & Emerging uses for genomic information in drug discovery. N. Engl. J. Med. 338, 125–126 (1998).

  22. 22.

    et al. Genetic wiring maps of single-cell protein states reveal an off-switch for GPCR signalling. Nature 546, 307–311 (2017).

  23. 23.

    et al. Haploid genetic screens in human cells identify host factors used by pathogens. Science 326, 1231–1235 (2009).

  24. 24.

    et al. Analysis of 589,306 genomes identifies individuals resilient to severe Mendelian childhood diseases. Nat. Biotechnol. 34, 531–538 (2016).

Download references

Author information

Affiliations

  1. Laura DeFrancesco is Senior Editor at Nature Biotechnology;

    • Laura DeFrancesco
  2. Malorye Allison Branca is a freelance writer based in Acton, Massachusetts;

    • Malorye Allison Branca
  3. Ken Garber is a freelance writer based in Ann Arbor, Michigan.

    • Ken Garber

Authors

  1. Search for Malorye Allison Branca in:

  2. Search for Ken Garber in:

  3. Search for Laura DeFrancesco in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.4121

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing